Experimental Models of Short Courses of Liposomal Amphotericin B for Induction Therapy for Cryptococcal Meningitis

Antimicrob Agents Chemother. 2017 May 24;61(6):e00090-17. doi: 10.1128/AAC.00090-17. Print 2017 Jun.

Abstract

Cryptococcal meningoencephalitis is a rapidly lethal infection in immunocompromised patients. Induction regimens are usually administered for 2 weeks. The shortest effective period of induction therapy with liposomal amphotericin B (LAMB) is unknown. The pharmacodynamics of LAMB were studied in murine and rabbit models of cryptococcal meningoencephalitis. The concentrations of LAMB in the plasma and brains of mice were measured using high-performance liquid chromatography (HPLC). Histopathological changes were determined. The penetration of LAMB into the brain was determined by immunohistochemistry using an antibody directed to amphotericin B. A dose-dependent decline in fungal burden was observed in the brains of mice, with near-maximal efficacy achieved with LAMB at 10 to 20 mg/kg/day. The terminal elimination half-life in the brain was 133 h. The pharmacodynamics of a single dose of 20 mg/kg was the same as that of 20 mg/kg/day administered for 2 weeks. Changes in quantitative counts were reflected by histopathological changes in the brain. Three doses of LAMB at 5 mg/kg/day in rabbits were required to achieve fungicidal activity in cerebrospinal fluid (cumulative area under the concentration-time curve, 2,500 mg · h/liter). Amphotericin B was visible in the intra- and perivascular spaces, the leptomeninges, and the choroid plexus. The prolonged mean residence time of amphotericin B in the brain suggests that abbreviated induction regimens of LAMB are possible for cryptococcal meningoencephalitis.

Keywords: Cryptococcus neoformans; cryptococcal meningitis; liposomal amphotericin B; meningoencephalitis; pharmacodynamics; pharmacokinetics.

MeSH terms

  • AIDS-Related Opportunistic Infections / drug therapy
  • AIDS-Related Opportunistic Infections / microbiology
  • Amphotericin B / pharmacokinetics*
  • Amphotericin B / therapeutic use*
  • Animals
  • Antifungal Agents / pharmacokinetics*
  • Antifungal Agents / therapeutic use*
  • Brain / microbiology
  • Cryptococcus neoformans / drug effects*
  • Dose-Response Relationship, Drug
  • Immunocompromised Host
  • Meningitis, Cryptococcal / drug therapy*
  • Meningitis, Cryptococcal / microbiology
  • Meningoencephalitis / drug therapy*
  • Meningoencephalitis / microbiology
  • Mice
  • Microbial Sensitivity Tests
  • Rabbits

Substances

  • Antifungal Agents
  • liposomal amphotericin B
  • Amphotericin B